Genialis, a leader in applied data science for the development of precision medicines, today announced a series of successes in its mission to help discover, develop and position of new therapies for the benefit of patients fighting complex diseases. Over the course of the year, Genialis initiated collaborations with numerous cutting edge biopharma, including Checkmate Pharmaceuticals and Oncologie, as well as renowned biotechnology leader Thermo Fisher Scientific.

Genialis began 2019 with a landmark event: the official launch of the Alliance for AI in Healthcare (AAIH) at Biotech Showcase held during the J.P. Morgan Healthcare Conference. The AAIH is the first industry advocacy organization dedicated to promoting responsible adoption and use of artificial intelligence to improve healthcare outcomes, from drug discovery to medical devices, point of care to payor efficiencies. Genialis is a founding member of the AAIH, with the company’s chief executive officer, Rafael Rosengarten, Ph.D., serving as a committee chair in 2019. Dr. Rosengarten will participate in an AAIH panel, titled, “The Impact of AI: How AI and ML are transforming R&D”, during this year’s Medtech Showcase on January 13, 2020, at 4:00 p.m. The panel discussion is open to the public and free of charge with a reception to follow. 

Read the press release in its entirety here.

Share this story, choose your platform!